AbbVie vs Veeva

AbbVie Highlights New Real-World Data Supporting the Effectiveness of VRAYLAR® (cariprazine) at Psych Congress 2026

New data from prospective real-world studies of VRAYLAR showed meaningful improvements in depressive symptoms, functioning and quality of life among adults living with major depressive disorder...

AbbVie Extends Migraine Leadership with Positive Phase 3 Atogepant Results in Menstrual Migraine

AbbVie announced positive Phase 3 results for atogepant in menstrual migraine, extending its leadership in migraine treatment. The company also declared a quarterly dividend of $1.73 per share and reported positive topline results from the Phase 3 CERVINO trial for etentamig in multiple myeloma.

AbbVie Announces Positive Topline Results from the Phase 3 CERVINO Trial Showing Etentamig Significantly Improved Response Rate and Progression-Free Survival in Patients with Relapsed/Refractory Multiple Myeloma

Etentamig, an investigational asset, achieved a significantly improved objective response rate (ORR, 74%) and a 60% risk reduction in disease progression or death (progression-free survival,...

10-Q Financial Filing Analysis for Veeva (2026-08-27)

Veeva Systems Inc. reported strong financial results for the second quarter of fiscal year 2027 ended July 31, 2026, with total revenue rising 18% year-over-year to $927.96 million. Top-line expansion was driven by a 16% increase in core subscription revenues to $766.76 million alongside a 24% rise in professional services to $161.20 million, driving GAAP operating income up to $275.02 million from $195.91 million in Q2 FY2026. Operationally, Veeva advanced its major migration of CRM customers from Salesforce to its proprietary Vault CRM platform (supported through 2029) and integrated Rise Healthcare Tech (Ostro), an AI-driven engagement platform acquired for $90 million, while deploying $246 million toward share repurchases.

• Q2 FY2027 total revenue grew 18% YoY to $927.96 million, led by $766.76 million in subscription revenue and $161.20 million in professional services, yielding a GAAP operating income of $275.02 million.
• The strategic migration from Salesforce to the proprietary Vault CRM platform continues ahead of the December 31, 2029 support deadline.
• Capital allocation included the $90 million ($70 million net of cash) acquisition of AI engagement platform Rise Healthcare Tech (Ostro) and the repurchase of 1,408,414 shares of common stock for approximately $246 million.

Eli Lilly Selects Veeva Vault CRM Globally

Veeva Systems announced that Eli Lilly and Company has committed to Veeva Vault CRM for global deployment. Vault CRM, part of Veeva's Vault CRM Suite, is described as the technology foundation for “agentic commercial,” a commercial model that leverages AI to deliver medicines to patients. Giuseppe Firenze, senior vice president, U.S. HCP and field engagement hub at Lilly, and Veeva CEO Peter Gassner are quoted on the strategic expansion. Veeva is described as an industry cloud provider for life sciences serving more than 1,500 customers and operating as a Public Benefit Corporation. The announcement was distributed via PR Newswire and published on MarTech Series on August 11, 2026.

• Veeva Systems announced that Eli Lilly and Company has committed to Veeva Vault CRM globally.
• Vault CRM is part of the Vault CRM Suite and is positioned as the technology foundation for the 'agentic commercial' model that leverages AI.
• Giuseppe Firenze, senior vice president, U.S. HCP and field engagement hub at Lilly, said Vault CRM will help Lilly bring breakthrough medicines to more patients.